NetraMark Holdings ( (TSE:AIAI) ) has shared an announcement.
NetraMark Holdings Inc. has made significant corporate advancements, including appointing Dr. Angelico Carta as Chief Strategy Officer, who will enhance the company’s pharmaceutical strategy. A strategic collaboration with a top pharmaceutical company aims to improve treatments for autoimmune disorders using NetraAI technology. The addition of P.J. Haley to the Board of Directors will support expansion into oncology, and a $1.16 million financial boost from warrant and stock option exercises will fund further AI solution development.
More about NetraMark Holdings
NetraMark Holdings Inc. is a leader in generative AI software focused on clinical trial analytics. The company specializes in AI-driven capabilities to enhance clinical trials and precision medicine, collaborating with major pharmaceutical companies to leverage technology for novel patient insights and treatment development.
YTD Price Performance: -6.43%
Average Trading Volume: 8,083
Technical Sentiment Consensus Rating: Sell
See more data about AIAI stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com